305 related articles for article (PubMed ID: 7083199)
1. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
Samojlik E; Santen RJ; Kirschner MA; Ertel NH
Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
[TBL] [Abstract][Full Text] [Related]
2. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Samojlik E; Veldhuis JD; Wells SA; Santen RJ
J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
4. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
Samojlik E; Santen RJ
J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
[TBL] [Abstract][Full Text] [Related]
5. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
[TBL] [Abstract][Full Text] [Related]
8. Basic studies on aminoglutethimide.
Salhanick HA
Cancer Res; 1982 Aug; 42(8 Suppl):3315s-3321s. PubMed ID: 7083193
[TBL] [Abstract][Full Text] [Related]
9. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
10. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
11. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
Samojlik E; Santen RJ; Wells SA
J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399
[No Abstract] [Full Text] [Related]
12. How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
Worgul TJ; Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336
[TBL] [Abstract][Full Text] [Related]
13. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
14. Joint effect of insulin-like growth factors and sex steroids on breast cancer risk.
Yu H; Shu XO; Li BD; Dai Q; Gao YT; Jin F; Zheng W
Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):1067-73. PubMed ID: 14578144
[TBL] [Abstract][Full Text] [Related]
15. Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women.
Kao YC; Okubo T; Sun XZ; Chen S
Anticancer Res; 1999; 19(3A):2049-56. PubMed ID: 10470147
[TBL] [Abstract][Full Text] [Related]
16. Aminoglutethimide--a new endocrine therapy in breast cancer. A cancer research review.
Harris AL
Exp Cell Biol; 1985; 53(1):1-8. PubMed ID: 3881300
[TBL] [Abstract][Full Text] [Related]
17. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
Bruning PF; Bonfrer JM; De Jong-Bakker M; Nooyen W
J Steroid Biochem; 1984 Sep; 21(3):293-8. PubMed ID: 6092781
[TBL] [Abstract][Full Text] [Related]
18. Resistance of the ovary to blockade of aromatization with aminoglutethimide.
Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1980 Sep; 51(3):473-7. PubMed ID: 6773974
[TBL] [Abstract][Full Text] [Related]
19. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
Geisler J; Lundgren S; Berntsen H; Greaves JL; Lønning PE
J Clin Endocrinol Metab; 1998 Aug; 83(8):2687-93. PubMed ID: 9709932
[TBL] [Abstract][Full Text] [Related]
20. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
